For patients
For patients with breast cancer
For patients with colon cancer
For patients with prostate cancer
For physicians
Oncotype DX Breast Recurrence Score
Oncotype DX Colon Recurrence Score
Oncotype DX Genomic Prostate Score
Contact
About us
News
CZ
EN
News
04. 10. 2019
New TAILORx Data: Clinical Outcomes in Patients with High Recurrence Score® Results
21. 08. 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
03. 07. 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test
30. 04. 2019
Results from the Czech OncotypeDX registry of patients with OncotypeDX Breast Recurrence Score results show up to 78% chemotherapy reduction
05. 03. 2019
Presentation about OncotypeDX Breast Recurrence Score at the 10th PragueOnco - Jubilee Interdisciplinary Oncology Colloquium
07. 09. 2018
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
03. 06. 2018
Landmark TAILORx Results Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the majority of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy